Management of testicular cancer: Practice survey in localized stage.
Journal
Canadian Urological Association journal = Journal de l'Association des urologues du Canada
ISSN: 1911-6470
Titre abrégé: Can Urol Assoc J
Pays: Canada
ID NLM: 101312644
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
medline:
15
8
2023
pubmed:
15
8
2023
entrez:
15
8
2023
Statut:
ppublish
Résumé
Management of testicular cancer requires a complete evaluation to confirm the localized stage and effective treatment according to guidelines to ensure the best outcome. The primary objective of this study was to evaluate practices at each stage of care in patients with a localized testicular tumor. The secondary objective was to evaluate the oncological prognosis of these patients according to the modalities of care. We conducted a multicenter practice evaluation study with retrospective collection and evaluation of patient records. The study was conducted in two French departments (population pool of 2 million inhabitants) between January 1, 2010, and January 31, 2015, enabling a five-year followup of patients. Patients presenting with stage I testicular tumor according to the American Joint Committee on Cancer classification were included in the analysis. A total of 226 records were analyzed; 93% of patients underwent bilateral scrotal ultrasound and 93.25% had a chest-abdomen-pelvis computed tomography scan. A total of 29.65% of patients had a preoperative tumor marker assay in accordance with guidelines; 94% of patients had a total orchiectomy, with a median time of 15 days. At the end of the followup period, 17 patients had suffered a recurrence of their disease. Providing adjuvant care in accordance with guidelines reduced the risk of recurrence in patients with a seminomatous tumor. Our study showed heterogeneity in compliance with guidelines for evaluation and effective treatment of patients with a localized testicular tumor. Some essential practices, such as assays of tumor markers and fertility preservation for patients over 40 years, were not well carried out. Adjuvant management of localized tumors appears to be an important predictor of recurrence.
Identifiants
pubmed: 37581556
pii: cuaj.8239
doi: 10.5489/cuaj.8239
pmc: PMC10426415
doi:
Types de publication
Journal Article
Langues
eng
Pagination
E236-E243Références
Clin Genitourin Cancer. 2017 Sep 6;:
pubmed: 28964691
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Clin Genitourin Cancer. 2014 Aug;12(4):292-9
pubmed: 24461624
Urol Oncol. 2009 Nov-Dec;27(6):604-10
pubmed: 18799329
Br J Cancer. 1995 Nov;72(5):1307-11
pubmed: 7577488
Prog Urol. 2018 Nov;28(12S):S147-S164
pubmed: 30472999
Eur Urol Focus. 2021 Sep;7(5):1137-1142
pubmed: 33121935
Medicine (Baltimore). 2018 Sep;97(37):e12390
pubmed: 30213007
Eur J Cancer Care (Engl). 2019 Jan;28(1):e12917
pubmed: 30252174
Eur Urol. 2020 Feb;77(2):139-141
pubmed: 31672465
Eur Urol. 2011 Aug;60(2):304-19
pubmed: 21632173
Ann Oncol. 2010 May;21 Suppl 5:v140-6
pubmed: 20555065
Ann Oncol. 2013 Feb;24(2):508-513
pubmed: 23110807
Cancer Epidemiol. 2019 Feb;58:175-177
pubmed: 30616087
Prog Urol. 2010 Nov;20 Suppl 4:S297-309
pubmed: 21129648
Andrology. 2018 Sep;6(5):798-804
pubmed: 29952145
J Urol. 2017 Mar;197(3 Pt 1):684-689
pubmed: 27663460
Cancer. 2006 Jan 15;106(2):313-9
pubmed: 16342064